Purpose: To compare the treatment outcomes in patients with acute proximal deep vein thrombosis (DVT) and iliofemoral stenosis who underwent either direct stenting after AngioJet rheolytic thrombectomy or staged stenting after AngioJet thrombectomy plus catheter-directed thrombolysis with urokinase. Methods: From June 2014 to February 2016, 91 DVT patients underwent 2 treatments for duplex-verified iliofemoral stenosis: direct stenting (n = 46; mean age 54.8 years; 32 men) or staged stenting (n = 45; mean age 56.5 years; 27 men). The degree of patency after thrombectomy or thrombolysis was evaluated using the Venous Registry Index (VRI), while the risk of postthrombotic syndrome (PTS) was evaluated according to the Villalta scale. Patients were followed with periodic duplex ultrasound scans up to 1 year. Results: The technical success rates were 100% in both groups; there was no 30-day mortality. Immediate (24-hour) clinical improvement was achieved in 42 (91%) of 46 direct group patients vs 33 (73%) of 45 staged group patients (p<0.001). A significant reduction (p<0.001) in the length of hospital stay was noted in the direct group (4.59±0.91) compared with that in the staged group (5.8±1.6). The stents used in the direct group were longer but with similar diameter compared with the staged group. The thrombolysis rates were 81.50%±5.76% in the direct group and 85.67%±3.84% in the staged group (p<0.001). The VRIs declined (improved) significantly in both groups (11.68±1.92 to 3.21±1.44 in the direct group and 12.17±2.29 to 2.36±1.19 in the staged group, both p<0.001). The Villalta scores were significantly better in the staged group (p<0.001). Recurrent DVT occurred in 2 patients in the direct group. The primary patency rates at 1 year were 93.5% in the direct group and 97.8% in the staged group (p=0.323). Conclusion: Both direct and staged stenting are effective treatment modalities for patients with acute proximal DVT. Compared with staged stenting, direct stenting provides similar treatment success and a significant reduction in the length of hospital stay; however, it has lower thrombolysis efficacy, and the risk of PTS at 1 year is greater with direct stenting.
Introduction
Lower extremity venous thrombosis has been identified as a serious public health issue because of the significant rates of associated morbidity and mortality. 1, 2 Among the various types of thromboses, iliofemoral deep venous thrombosis (DVT) has the greatest risk for complications, including pulmonary embolism and postthrombotic morbidity, which decrease patient quality of life. Fifteen percent of patients develop venous ulcers within 5 years and 40% experience venous claudication. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Most practice guidelines recommend early and rapid clot removal for patients with iliofemoral DVT to maintain good functional abilities, an acceptable life expectancy, and a low risk of bleeding complications. 10, [13] [14] [15] [16] [17] The percutaneous removal of thrombus burden, which may theoretically restore venous valvular function and minimize venous reflux while reducing procedure-related endothelial damage, [18] [19] [20] has been the main therapeutic objective of many endovascular strategies, including catheter-directed thrombolysis (CDT) and percutaneous mechanical thrombectomy (PMT).
Among the various thrombectomy devices that have been clinically tested, the AngioJet rheolytic thrombectomy system (Boston Scientific, Marlborough, MA, USA) is representative because it allows simultaneous thrombolytic infusion followed by thrombus extraction without harming valve function. [20] [21] [22] [23] [24] The majority of previous studies have used the AngioJet as an adjuvant therapy for rapid clot removal. The AngioJet has seldom been used alone. [22] [23] [24] Treating DVT patients with underlying iliofemoral vein stenosis involves a decision as to when a stent should be released: immediately after thrombectomy or after thrombolysis. To inform this decision, the present single-center study compared the procedure and treatment outcomes of DVT patients with underlying iliofemoral vein stenosis treated using either direct stenting following AngioJet alone or staged stenting after AngioJet plus overnight CDT.
Methods

Study Participants
The retrospective analysis involved patients who experienced an initial episode of DVT (within 14 days of symptom onset) and had first-time iliofemoral vein thrombosis objectively verified by duplex ultrasound. Patients with an increased risk of bleeding or contraindication to thrombolysis or anticoagulation were not eligible. From June 2014 to February 2016, 91 patients provided written informed consent for iliac or iliofemoral stent implantation and underwent direct stenting after AngioJet rheolytic thrombectomy (n=46; mean age 54.8 years; 32 men) or staged stenting after AngioJet thrombectomy plus CDT (n=45; mean age 56.5 years; 27 men). Table 1 lists the patient characteristics and risk factors for venous thrombosis. The left limb was most commonly affected. Furthermore, no patients had isolated thrombi in the inferior vena cava (IVC).
Treatment
All patients received low-molecular-weight heparin (200 U/ kg dalteparin; Pfizer, New York, NY, USA) or enoxaparin (1.0 mg/kg; Sanofi, Paris, France) on the day of diagnosis according to local routines based on international guidelines. 13 Venograms were performed from the ipsilateral dorsal vein. Retrievable IVC filters were routinely placed via a contralateral femoral puncture to prevent pulmonary embolism (PE) according to our national guideline. 25 Next, the patient was placed in the prone position, and the ipsilateral popliteal vein was accessed using a 6-F Radifocus Introducer II (Terumo Medical Corp, Tokyo, Japan) under ultrasound guidance (SonoSite 180 plus; SonoSite, Bothel, WA, USA).
In the direct group, the AngioJet system was routinely used as previously described [21] [22] [23] [24] with slight modification. After initial ascending venography via an introducer sheath, the AngioJet catheter was advanced over a 260-cm stiff Glidewire (Boston Scientific) and through the thrombosed vein segment. First, a power pulse lytic model was used with 0.25×10 6 units of urokinase (Tianpu Pharmaceutical Biochemical Medicine Co, Ltd, Guangzhou, China) in 250 mL of saline. Fifteen minutes was allowed for the pharmacological thrombolytic effect then the AngioJet catheter was placed in its standard rheolytic thrombectomy mode. This sequence was repeated if significant residual thrombi remained on subsequent venograms. A maximum 500 mL of suction fluid were used. Stent placement via the ipsilateral popliteal puncture was indicated by residual iliac vein stenosis. The diameter of the angioplasty balloon matched the size of the iliac vein adjacent to the lesion. A Wallstent (Boston Scientific) 20% larger and 2 cm longer than the stenotic segment was deployed.
In the staged group, AngioJet thrombectomy was followed by introduction of a multiple-side-hole infusion catheter with an infusion length of 30 to 50 cm (Angiodynamics, Queensbury, NY, USA) into the thrombotic segment.
Urokinase (30,000-50,000 U/100 mL/h) was injected, and the activated partial thromboplastin time and fibrinogen level were measured every 4 hours. When the fibrinogen level reached 1.5 g/L, the urokinase dosage was halved, and when it was decreased to 1.0 g/L, urokinase was replaced with heparinized saline. Venography and stent placement as described above were performed the next day.
Warfarin, rivaroxaban (10 mg/d), or other anticoagulant agents were prescribed for at least 6 months, and the international normalized ratio was maintained between 2 and 3. All the patients used compression stockings (class II, 30 mm Hg) as a standard adjunct treatment.
Clinical follow-up visits were scheduled at 2 weeks and at 1, 3, 6, and 12 months after the procedure. A Doppler scan was performed to assess patency and valve function as a routine part of follow-up.
Definitions
Technical success was defined as complete stent coverage of the lesion. Immediate clinical improvements referred to a decrease in pain or swelling of the affected extremity within 24 hours of intervention. Primary patency extended from the time of the intervention to the first recurrence of either thrombosis of the threatened segment or an intervention to maintain patency. 26 A serious adverse event referred to any sequela that was fatal or life threatening, resulted in persistent or significant disability, required an intervention to prevent permanent impairment/damage, or resulted in readmission or prolonged hospitalization. Accordingly, nonserious events required no or nominal treatment without additional/ prolonged hospitalization.
Major bleeding events were intracranial bleeding or bleeding that was sufficiently severe to result in death, surgery, the cessation of therapy, or blood transfusion. 16 The loss of clinical benefit at follow-up was defined as recurrent thrombosis or a patient report of a worsening condition in the treated limb.
The venograms were used to assess the degree of patency after thrombectomy or thrombolysis according to the Venous Registry Index (VRI), which has been previously described 27, 28 and was used with little modification. The VRI scoring system included 7 venous segments: common iliac vein, external iliac vein, common femoral vein, femoral vein (proximal, middle and distal), and popliteal vein. The criteria for scoring are the following: completely free of thrombus (0), partially occluded (1), and completely occluded (2) . The maximum score is 14, signifying total occlusion in all segments.
Venous reflux, an important predictive factor for the development of postthrombotic syndrome (PTS), was defined as a valve closure time >0.5 seconds after distal compression in the standing position as assessed with duplex ultrasound. The grades were defined as follows: grade 1, <0.5 second grade 2, 0.5 to 1.0 second and grade 3, >1 second. 29 The risk of PTS was evaluated according to the Villalta score, 30 an objective scoring system that includes evaluations of pain, varicose veins, edema, hyperpigmentation, inflammation, induration, and active ulcers, which are classified according to number, duration, and size. The patient's compliance with the compression therapy was also considered. The patients' scores for each item were graded as follows and subsequently summarized: none (0), mild (1), moderate (2), and severe (3).
Statistical Analysis
Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage). The statistical analyses of the categorical variables were performed with Fisher exact or Pearson's chi-square tests. The primary patency of both groups was estimated using the Kaplan-Meier method, survival curves were compared using the log-rank test. The threshold of statistical significance was p<0.05. The data were analyzed with SPSS statistical software (version 15.0; IBM Corporation, Armonk, NY, USA) and Stata (version 13.0; Stata Corporation, College Station, TX, USA). Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage). b There were no significant differences between groups.
Results
Procedure
The technical success rates were 100% in both groups. The mean total dose of urokinase in the staged group was 0.54×10 6 units (range 0.35-0.75×10 6 ) administered over a mean of 11.38 hours (range 7-16); the mean time to stenting was 14.13 hours (range 9-18).
No 30-day mortality or major bleeding occurred in these patients (Table 2 ), but minor bleeding was observed in 1 patient in the staged group. Moreover, no symptomatic PE was diagnosed during hospitalization. There was no significant difference in the postoperative complications between the 2 groups.
Immediate clinical improvement was achieved in 42 (91%) of 46 direct group patients vs 33 (73%) of 45 staged group patients (p<0.001). Hematuria from the hemolysis caused by the AngioJet was observed in 37 patients in the direct groups and 39 patients in the staged group. There was no hyperkalemia, anuria, or bradycardia in either group.
Follow-up
Three patients (1 direct and 2 staged) were lost at the 12-month follow-up; the others were followed for >12 months. The VRIs declined (improved) significantly in both groups (11.68±1.92 to 3.21±1.44 in the direct group and 12.17±2.29 to 2.36±1.19 in the staged group; both p<0.001). The thrombolysis rates were 81.50%±5.76% in the direct group and 85.67%±3.84% in the staged group (p<0.001). Serial duplex ultrasound scans revealed significant improvements in the thrombus burden in both groups, with stable thrombus status maintained.
The grades of venous reflux were 1.36±0.46 in the direct group and 1.26±0.41 in the staged group at the 12-month follow-up (p=0.139). With regard to PTS, the Villalta scores revealed a significant difference (direct: 4.20±2.47 vs staged: 2.13±1.91, p<0.001), suggesting a lower risk of PTS in the staged group.
In terms of primary patency, 2 patients in the direct group experienced recurrent DVT during the first and seventh months and underwent repeat CDT. Subsequently, the symptoms of both patients were improved. The primary patency rates at 1 year were 93.5% in the direct group and 97.8% in the staged group (p=0.323; Figure 1 ).
Discussion
While the technical feasibility and efficacy of AngioJet thrombectomy for iliofemoral DVT have been validated in several studies, [22] [23] [24] our investigation focused on the timing of stent implantation in patients with iliac vein stenosis. Compared with the staged strategy, direct stenting was clearly able to immediately open the passage and quickly relieve the symptoms of swelling, which resulted in a corresponding reduction in hospitalization time and better 24-hour clinical improvement. The main reason for this difference may be that longer stents were needed to cover all of the possible lesions in the direct group, and 2 stents were occasionally required. However, after thrombolysis in the staged group, it was possible to better define the stenosis and select a stent that matched the actual lesion. During follow-up, the patency rates of the 2 groups were similar, but there were 2 recurrent episodes of DVT in the direct group vs none in the staged group. Although there was no statistical significance to this difference due to the small sample size, it may be that the likelihood of recurrent DVT is enhanced by residual thrombi around the stent and the use of a long stent. The efficacy of AngioJet thrombectomy for DVT has previously been reported, [22] [23] [24] although there is wide disparity in the rates of thrombus clearance (23.5%-90.0%). In our study, the efficacy of thrombolysis was significantly better in the staged group, which suggests that a combination of PMT and CDT may be better than AngioJet use alone. Previous studies 24, 31 also observed that the addition of CDT improved the efficacy of PMT and resulted in shorter procedure times and satisfactory patient outcomes. From the imaging perspective, the walls and valves of the veins after thrombolysis were smoother than before the procedures (Figure 2) .
The cause of PTS is residual thrombotic injury to the venous valvular apparatus, which produces chronic venous insufficiency that may in turn result in recurrent leg swelling, ulceration, cellulitis, and even rehospitalization. Rapid and short-term mechanical suction cannot clear thrombi hidden in the valve fossa. As proposed by Sevitt et al, 32 progressive valve dysfunction is likely due to valve entrapment by a residual thrombus, which then results in fibrosis as part of the postthrombotic resolution of the clot.
The preservation of the valves did not differ between groups at 1 year. However, the Villalta scores were significantly better in the staged group. This finding indicates that the PTS may not be correlated with valve preservation. The residual thrombotic tissue that is not dissolved causes longterm valve fibrosis that will continue to damage the valve. Therefore, long-term follow-up is needed. This phenomenon has also been reported in another study 23 and may explain the correlation between quality of life and lytic success observed in a previous study.
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Conclusion
Based on our relatively small single-center experience with 1-year follow-up, both direct and staged stenting are effective treatment modalities for DVT patients with iliofemoral stenosis. Compared with the staged stenting strategy, direct stenting provides similar treatment success, quicker clinical improvement, and a significant reduction in the length of hospital stay. However, it has lower thrombolysis efficacy, and the risk of PTS at 1 year is greater with direct stenting. Importantly, our study provided meaningful guidance for the use of stents in this clinical setting. Additional clinical studies are necessary to further verify the timing of stenting that is most beneficial to the patient. A large-scale prospective study will unquestionably provide further insight regarding this unresolved clinical question.
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